docwirenews.com
Cure8 news brief
Why This Matters
If confirmed, starting effective biologic therapy at diagnosis could lower the chance of surgery and complications over several years for people with moderate-to-severe Crohn’s disease.
This may be especially relevant for newly diagnosed patients facing choices about early aggressive treatment versus a stepwise approach.
Who Should Pay Attention
Newly diagnosed Crohn’s disease patients, adult patients considering early biologic therapy, gastroenterologists, IBD clinicians, and researchers studying treatment strategies and long-term outcomes.
Study Snapshot
Story typeResearch news
Evidence typePhase 3 clinical trial
Source depthFull source text
What To Know
This follow-up suggests that starting effective biologic-based therapy (in this trial, infliximab plus an immunomodulator such as azathioprine, low-dose mercaptopurine with allopurinol, or methotrexate) at diagnosis reduced the need for abdominal surgery and slowed progression compared with initial step-up care.
The main outcomes reported were rates and timing of Crohn’s-related abdominal surgery, disease progression, and hospital admissions over 5 years. The trial randomized 386 newly diagnosed patients and followed available records for 358.
After 48 weeks on protocol therapy patients returned to standard local care for the remainder of follow-up; the analysis compares outcomes by original randomization group over 5 years.
These results are presented as evidence that early effective therapy can modify disease course, but individual treatment decisions depend on many factors including risks, preferences, and local care pathways.
Keep In Mind
This is a randomized trial follow-up published in a peer-reviewed journal (Lancet Gastroenterology & Hepatology). After the first 48 weeks patients returned to local standard care, so downstream treatments varied and may affect long-term outcomes. Treatment decisions should be individualized; this article summarizes trial results but does not replace clinical advice.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationdocwirenews.com
Indexed viaGoogle News
Source typeWeb article
PublishedSep 25, 2026, 1:03 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
'Top-down' therapy linked to fivefold lower risk for abdominal surgery in Crohn's disease
Early “top-down” infliximab plus an immunomodulator was linked to much lower 5-year risk of abdominal surgery, disease progression, and hospitalization versus a step-up approach. This could influence treatment planning...
Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trial.
If confirmed, starting anti‑TNF therapy (infliximab) early plus an immunomodulator may reduce surgeries, hospital admissions, and progression to complicated disease behavior over 5 years compared with a traditional...
Top-Down Therapy in Crohn’s Disease Linked to Improved 5-Year Outcomes
The study suggests starting anti-TNF therapy with an immunomodulator at diagnosis may reduce surgery, hospital stays, and progression to complicated Crohn’s over 5 years — outcomes that matter to patients and clinicians...